Plasmid Engineering

Start strong by designing the right plasmid construct for your gene editing system. Our SnapFast® platform and custom plasmid engineering services help ensure high transgene expression, yield, and control — from CRISPR payloads to viral vector packaging.

With proven expertise in complex genes of interest, we can boost vector yields by up to 3-fold through advanced plasmid optimization.

Viral Vector Services

We know that Viral Vector is a significant component, and a significant cost element of gene edited autologous cell therapies. We can help not only with scalable manufacturing of AAV and LVV built for gene-modified cell therapy but also help you scale and reduce costs. From plasmid supply to final fill, we support seamless vector production under GMP.

Cell Therapy Services

Minaris provides comprehensive end-to-end CDMO support for autologous therapies, encompassing process development, GMP manufacturing and global distribution. Our extensive experience in gene-edited autologous CAR-T, TIL, HSC and Treg cells ensures program success. We routinely use state-of-the-art closed and automated manufacturing solutions that help you achieve your goals and commercialize successfully.

During process development (PD) we assess the suitability of current platforms and provide scale-up or scale-out solutions for your Cell Therapy. During this phase we also evaluate all raw materials for GMP use and provide a comprehensive data package for your CMC submissions.

Testing Services

Robust, scalable, and timely in-process and release testing is a critical element of Autologous Cell Therapy. Through our extensive in-house testing capabilities, we streamline processes so patients receive the therapy safely and quickly. We offer biosafety, identity, potency, stability, and release assays co-located and integrated with manufacturing.

During analytical development (AD) and tech transfer, we evaluate all assays to be scientifically sound and fit-for-purpose. State-of-the-art equipment is used for in-process control testing as well as future release testing. Surrogate assays for potency assessment and potency assurance programs can be developed concurrently. In-use stability studies or on/off target sequencing analysis needed? No problem! Speak with our analytical experts to learn more about our experience and ever-increasing offerings. We can even provide a comprehensive data package for your CMC submission.